People

Lili Guo

Great Point Partners senior analyst on its public equity team, joining in 2025. Previously evaluated biotechnology therapeutics at Braidwell and conducted preclinical research at Regeneron. Holds a University of Pennsylvania cell and molecular biology PhD and completed pharmacology postdoctoral research there.